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BACKGROUND
Levosimendan is a calcium-sensitizing drug with inotropic and other properties 
that may improve outcomes in patients with sepsis.
METHODS
We conducted a double-blind, randomized clinical trial to investigate whether 
levosimendan reduces the severity of organ dysfunction in adults with sepsis. 
Patients were randomly assigned to receive a blinded infusion of levosimendan 
(at a dose of 0.05 to 0.2 μg per kilogram of body weight per minute) for 24 hours 
or placebo in addition to standard care. The primary outcome was the mean daily 
Sequential Organ Failure Assessment (SOFA) score in the intensive care unit up to 
day 28 (scores for each of five systems range from 0 to 4, with higher scores indicat-
ing more severe dysfunction; maximum score, 20). Secondary outcomes included 
28-day mortality, time to weaning from mechanical ventilation, and adverse 
events.
RESULTS
The trial recruited 516 patients; 259 were assigned to receive levosimendan and 
257 to receive placebo. There was no significant difference in the mean (±SD) 
SOFA score between the levosimendan group and the placebo group (6.68±3.96 vs. 
6.06±3.89; mean difference, 0.61; 95% confidence interval [CI], −0.07 to 1.29; 
P = 0.053). Mortality at 28 days was 34.5% in the levosimendan group and 30.9% 
in the placebo group (absolute difference, 3.6 percentage points; 95% CI, −4.5 to 
11.7; P = 0.43). Among patients requiring ventilation at baseline, those in the levo-
simendan group were less likely than those in the placebo group to be success-
fully weaned from mechanical ventilation over the period of 28 days (hazard ratio, 
0.77; 95% CI, 0.60 to 0.97; P = 0.03). More patients in the levosimendan group than 
in the placebo group had supraventricular tachyarrhythmia (3.1% vs. 0.4%; absolute 
difference, 2.7 percentage points; 95% CI, 0.1 to 5.3; P = 0.04).
CONCLUSIONS
The addition of levosimendan to standard treatment in adults with sepsis was not 
associated with less severe organ dysfunction or lower mortality. Levosimendan 
was associated with a lower likelihood of successful weaning from mechanical 
ventilation and a higher risk of supraventricular tachyarrhythmia. (Funded by the 
NIHR Efficacy and Mechanism Evaluation Programme and others; LeoPARDS 
Current Controlled Trials number, ISRCTN12776039.)
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Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection1 and is a leading 
cause of death worldwide. Septic shock is the 
most severe form of the condition and results in 
circulatory and metabolic abnormalities.2 Per-
sisting hypotension despite adequate fluid resus-
citation is due to a combination of profound 
vasodilatation, vascular hyporeactivity to catechol-
amines, and myocardial depression.3 Although 
catecholamines are the recommended first-line 
therapy for septic shock,4 high doses of admin-
istered catecholamines and high levels of circu-
lating catecholamines are associated with poor 
outcomes and severe side effects, including 
myocardial injury and peripheral ischemia.5-7
Levosimendan is a calcium-sensitizing drug 
with inotropic and vasodilator properties that is 
licensed in numerous countries (not including 
the United States) to treat decompensated heart 
failure.8 In contrast to catecholamines, levosimen-
dan causes increased myocardial contraction with 
a minimal increase in oxygen demand,9 and dia-
stolic relaxation is not impaired. Small studies 
that have investigated the use of levosimendan 
in patients with septic shock have shown improve-
ments in hemodynamic variables,10 microcircu-
latory flow,11 and renal10 and hepatic12 function, 
as compared with dobutamine. Other important 
noninotropic effects have also been shown, includ-
ing antiinflammatory,13 antioxidative,14 and anti-
apoptotic15 effects and possibly protection from 
ischemia and reperfusion injury.16 A recent meta-
analysis supported the use of levosimendan in pa-
tients with sepsis, but only 125 patients in total 
had been treated.17 The Levosimendan for the 
Prevention of Acute Organ Dysfunction in Sepsis 
(LeoPARDS) trial was designed to test whether 
the addition of levosimendan to standard care 
would reduce the severity of organ dysfunction 
among patients with septic shock and to assess 
its safety profile in patients with this condition.
Me thods
Trial Design and Participants
We conducted this multicenter, randomized, 
double-blind, placebo-controlled clinical trial 
in 34 general adult intensive care units (ICUs) in 
the United Kingdom. The trial protocol, avail-
able with the full text of this article at NEJM.org, 
was designed by the trial management commit-
tee and has been published previously.18 The 
London–Harrow Research and Ethics Commit-
tee approved the protocol.
The trial was funded by the National Institute 
for Health Research and Tenax Therapeutics and 
sponsored by Imperial College London. Data 
management and analysis were performed by 
the Imperial Clinical Trials Unit. Orion Pharma 
provided levosimendan and placebo free of 
charge. The funders, the sponsor, and Orion 
Pharma had no role in designing the trial, gath-
ering or analyzing the data, writing the manu-
script, or making the decision to submit the 
manuscript for publication. The first author 
vouches for the data and analyses, as well as for 
the fidelity of this report to the trial protocol.
Enrollment Criteria and Randomization
Adult patients who had septic shock and had 
received vasopressors for at least 4 hours were 
eligible for inclusion. Detailed inclusion and ex-
clusion criteria are provided in the Supplemen-
tary Appendix, available at NEJM.org. Patients 
had to be recruited within 24 hours after meet-
ing the inclusion criteria. Written informed con-
sent was obtained from either the patient or, in 
the event that the patient lacked capacity, a per-
sonal or professional legal representative before 
enrollment in the trial. Retrospective written 
informed consent was sought from the patient 
once capacity was regained.
Enrollment, randomization, and data collec-
tion were performed by means of an online sys-
tem (InForm, Oracle). Patients were assigned in 
a 1:1 ratio to receive levosimendan or placebo, 
with the use of variable block sizes of four and 
six and computer-generated random numbers 
and with stratification according to recruitment 
center. The randomization sequence was prepared 
by an independent statistician. Trial-specific la-
beling and packaging, to ensure that trial packs 
were identical, was undertaken by Victoria Phar-
maceuticals. Patients and clinical and research 
staff remained unaware of the trial-group assign-
ment throughout the trial.
Clinical Treatment
Patients were assigned to receive a blinded in-
fusion of either levosimendan or placebo for 
24 hours in addition to standard care. Fig. S1 in 
the Supplementary Appendix shows the infusion 
algorithm. No bolus loading dose was given. 
The administration of levosimendan or placebo 
was started at a rate of 0.1 μg per kilogram of 
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body weight per minute and, in the absence 
of rate-limiting side effects, was increased after 
2 to 4 hours to 0.2 μg per kilogram per minute 
for a further 20 to 22 hours. Patients received 
intravenous fluid boluses for any clinically sig-
nificant drop in blood pressure and, if neces-
sary, vasopressors were adjusted to maintain an 
adequate blood pressure. If the patient had rate-
limiting side effects — either hypotension or 
severe tachycardia (heart rate >130 beats per 
minute, or an increase of >20% if the heart rate 
was already >110 beats per minute) — at the 
dose of 0.2 μg per kilogram per minute, then 
the infusion rate was reduced to 0.1 μg per kilo-
gram per minute. If necessary to avoid hypoten-
sion or severe tachycardia, the rate was reduced 
to 0.05 μg per kilogram per minute or even dis-
continued.
Other aspects of clinical care were at the dis-
cretion of the local physician and were based on 
the Surviving Sepsis Campaign guidelines (see 
the Supplementary Appendix).4 The trial protocol 
recommended a mean arterial pressure of 65 to 
70 mm Hg. This pressure could be varied for 
individual patients, but investigators were en-
couraged to use the lowest dose of vasopressor 
that maintained tissue perfusion in each patient. 
Additional inotropic agents could be used as 
clinically indicated (i.e., for ongoing low cardiac 
output after fluid resuscitation). Dobutamine 
was the recommended inotrope, with lowering 
of the dose and discontinuation once adequate 
oxygen delivery had been achieved.
Outcome Measures
The primary trial outcome was the mean daily 
Sequential Organ Failure Assessment (SOFA) 
score19 while the patient was in the ICU, as mea-
sured from randomization to a maximum of 
28 days. The daily SOFA score after baseline was 
calculated for each patient on the basis of five 
organ systems: cardiovascular, respiratory, renal, 
hepatic, and coagulation systems. (Scores for 
each system range from 0 to 4, with higher scores 
indicating more severe organ-system dysfunc-
tion; maximum score, 20.) The neurologic system 
was not included, as in some previous trials,20,21 
owing to the difficulties of accurately scoring 
the Glasgow Coma Score daily in the presence 
of sedation. Daily scores were totaled for each 
patient’s ICU stay and divided by the number of 
days that they remained in the ICU in order to 
calculate the mean SOFA score for that patient.
To assess the effect of levosimendan on indi-
vidual organ systems, the individual SOFA com-
ponents were analyzed, and several other clinical 
outcomes were determined a priori for second-
ary analyses. These outcomes included the num-
ber of catecholamine-free and ventilator-free days, 
the time to weaning from mechanical ventila-
tion, the proportion of patients with a major 
acute kidney event22 over a period of 28 days 
(defined as death, new requirement for renal-
replacement therapy, or sustained renal failure 
[stage 2 or 3 acute kidney injury23] at day 28), 
and the duration of renal-replacement therapy. 
Mortality rates at 28 days, at ICU discharge, and 
at hospital discharge, as well as the length of 
stay in the ICU and serious adverse events, were 
also recorded.
Statistical Analysis
We calculated that a sample of 500 patients 
would provide the trial with 90% power to detect 
a difference of 0.5 points in the mean SOFA 
score, assuming a standard deviation of 1.5 and 
a significance level of 0.05.19 To allow for a 3% 
rate of withdrawal of consent, the recruitment 
target was 516 patients.
The primary analysis was unadjusted in the 
intention-to-treat population, and reported the 
difference in mean SOFA scores between the two 
trial groups. Because the mean SOFA score was 
not normally distributed, 95% confidence inter-
vals of the mean difference were calculated with 
the use of bootstrapping, with the application of 
the percentile method with 100,000 samples. We 
used a priori defined regression models to inves-
tigate whether the main analysis was sensitive to 
adjustment for trial-center (i.e., ICU) effects, age, 
and severity of illness (according to the Acute Phy-
siology and Chronic Health Evaluation [APACHE] 
II score) with bootstrapped confidence intervals.
Because levosimendan is an inotrope with 
prolonged hemodynamic effects but is not in-
cluded as part of the cardiovascular scoring 
within the SOFA score, the primary analysis was 
repeated with the exclusion of the cardiovascular 
component as a sensitivity analysis. We prespeci-
fied the use of Bayesian models of multiple im-
putation for missing data, as described in the 
Supplementary Appendix; we also performed 
post hoc analyses using imputation to account 
for any differential effect of treatment on the 
rates of ICU discharge or death before 28 days. 
Time-to-event data were described with the use 
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of Kaplan–Meier plots and Cox regression, with 
adjustment for age and APACHE II score, allow-
ing for clustering according to ICU.
Four subgroup analyses were planned a pri-
ori on the basis of the baseline measurement of 
the cardiac index, if measured (lowest third vs. 
middle and highest thirds), the central venous 
oxygen saturation (low [<70%], normal [70 to 
85%], or high [>85%]), the serum lactate level 
(≤2 mmol per liter vs. >2 mmol per liter), and 
the dose of norepinephrine (below vs. above the 
median infusion rate). The heterogeneity of treat-
ment effect according to subgroup was calcu-
lated with the use of a permutation test, which 
permuted both the subgroup and the trial-
group assignment.24 All the analyses were per-
formed with the use of R software, version 
3.2.2 (R Project for Statistical Computing).25 A 
P value of less than 0.05 was considered to in-
dicate statistical significance, with the use of 
two-sided tests; no corrections were made for 
multiple testing.
R esult s
Trial Participants
The trial ran from January 2014 through Decem-
ber 2015, when the required sample of 516 pa-
tients were enrolled. Fig. 1 shows the random-
ization and flow of patients in the trial; 259 
patients were assigned to receive levosimendan 
and 257 to receive placebo. A total of 8 patients 
(4 patients in each group) did not receive the as-
signed trial regimen. The family of 1 patient in 
the levosimendan group withdrew consent after 
randomization but before the drug was admin-
istered. This patient was excluded from all the 
analyses. The other 7 patients were included in 
the intention-to-treat analysis.
The two groups were well balanced at base-
line (Tables  1 and  2, and Tables S1 and S2 in 
the Supplementary Appendix). The median time 
to recruitment was 16 hours after the initiation 
of vasopressors, and the median dose of norepi-
nephrine was 0.28 μg per kilogram per minute 
at the time of starting the infusion.
Cardiovascular Effects
The infusion was discontinued before the 24-hour 
time point owing to hemodynamic instability 
(hypotension or tachycardia) in 33 of 244 patients 
(13.5%) in the levosimendan group, as compared 
with 19 of 248 patients (7.7%) in the placebo 
group. The mean arterial pressure was lower in 
the patients in the levosimendan group than in 
those in the placebo group in the first 24 hours 
(the duration of the infusion) but was similar 
thereafter in the two groups. The rate and dura-
tion of the norepinephrine infusion were higher 
in the levosimendan group than in the placebo 
group; there was also less frequent use of dobuta-
mine in the levosimendan group. The heart rate 
over the first 4 days was significantly higher in 
patients in the levosimendan group than in those 
in the placebo group. Intravenous-fluid adminis-
tration, fluid balance, and serum lactate levels 
were similar in the two groups. Details are pro-
vided in Table S3 and Fig. S2 through S6 in the 
Supplementary Appendix.
Outcomes
The percentage of daily SOFA scores that were 
missing ranged from 2.3% for the cardiovascu-
lar component to 12.8% for the liver component. 
The primary outcome, the mean (±SD) SOFA 
score over the stay in the ICU, was 6.68±3.96 in 
the levosimendan group and 6.06±3.89 in the 
placebo group (mean difference, 0.61; 95% con-
fidence interval [CI], −0.07 to 1.29; P = 0.053) 
(Table 3). After adjustment for ICU, age, and 
APACHE II score in a regression model, the 
mean difference in the score was 0.59 (95% CI, 
−0.02 to 1.20; P = 0.06). In an analysis that con-
sidered each component of the total SOFA score 
independently, the mean daily cardiovascular 
score was higher in the levosimendan group 
than in the placebo group (mean difference, 
0.25; 95% CI, 0.04 to 0.46; P = 0.01). The pre-
specified and post hoc sensitivity analyses did 
not materially change the result (Table 3, and 
Table S4 in the Supplementary Appendix). The 
total daily SOFA scores and individual compo-
nent scores are shown in Fig. S7 through S12 in 
the Supplementary Appendix.
Secondary outcomes are shown in Table 3. 
Mortality at 28 days was 34.5% in the levosimen-
dan group and 30.9% in the placebo group 
(mean difference, 3.6 percentage points; 95% CI, 
−4.5 to 11.7; P = 0.43). The Kaplan–Meier curves 
for survival to day 28 are shown in Figure 2. 
Among patients requiring mechanical ventila-
tion at baseline, those in the levosimendan 
group were less likely than those in the placebo 
group to be successfully weaned from mechani-
cal ventilation over the period of 28 days (hazard 
ratio, 0.77; 95% CI, 0.60 to 0.97; P = 0.03) (Fig. 
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Figure 1. Recruitment and Randomization of the Patients.
Patients could meet more than one exclusion criterion. Other reasons for nonenrollment included unavailability of 
levosimendan or placebo, mental health problems, language barrier, and unspecified reasons (in 78 patients). SIRS 
denotes the systemic inflammatory response syndrome.
516 Underwent randomization
2382 Patients were assessed for eligibility
1866 Were excluded
157 Were not in septic shock
12 Were <18 yr of age
41 Did not have an infection
43 Did not meet SIRS criteria
127 Did not meet vasopressor criteria
714 Were outside 24-hr window since
meeting inclusion criteria
82 Had end-stage renal failure
2 Had a history of torsades de pointes
83 Had severe hepatic impairment
61 Had obstructions affecting ventricular 
flow
352 Had a decision regarding treatment
limitation
47 Weighed >135 kg
4 Were pregnant
6 Had received levosimendan within
30 days
2 Had hypersensitivity to levosimendan
56 Were enrolled in another trial
43 Were not enrolled, per physician’s
decision
90 Did not give consent or have consent
obtained
85 Had problems with staff availability
102 Had other reasons
259 Were assigned to receive
levosimendan
258 Were included in primary analysis
1 Was excluded owing to withdrawal
of consent
257 Were included in primary analysis
255 Were included in as-treated analysis 253 Were included in as-treated analysis
257 Were assigned to receive
placebo
255 Received levosimendan
4 Did not receive levosimendan
1 Withdrew consent
2 Died
1 Had a clinical decision
to withhold drug owing to
improvement in condition
253 Received placebo only
1 Received placebo and open-label
levosimendan
3 Did not receive placebo
2 Died
1 Was enrolled during period in which
trial was temporarily halted
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Characteristic
Levosimendan 
(N = 258)
Placebo 
(N = 257)
Median age (IQR) — yr 67 (58–75) 69 (58–77)
Male sex — no. (%) 145 (56.2) 144 (56.0)
Median weight (IQR) — kg 76 (65–90) 80 (68–91)
Median body‑mass index (IQR)† 27 (23–30) 28 (24–32)
Race — no. (%)‡
Asian 11 (4.3) 10 (3.9)
Black 4 (1.6) 6 (2.3)
White 240 (93.0) 240 (93.4)
Other 3 (1.2) 1 (0.4)
History of recent surgery — no. (%)§ 94 (36.4) 95 (37.0)
Preexisting condition — no. (%)
Ischemic heart disease 46 (17.8) 31 (12.1)
Congestive heart failure 1 (0.4) 4 (1.6)
Cardiac failure 23 (8.9) 26 (10.1)
Severe COPD 16 (6.2) 11 (4.3)
Chronic renal failure 19 (7.4) 18 (7.0)
Cirrhosis 4 (1.6) 6 (2.3)
Immunocompromised condition 23 (8.9) 24 (9.3)
Diabetes 59 (22.9) 51 (19.8)
Beta‑blockers normally taken — no. (%) 54 (20.9) 45 (17.5)
Median time from shock to randomization (IQR) — hr¶ 16 (10–21) 15 (10–20)
Vasoactive‑drug dose at randomization
Norepinephrine
No. of patients 255 253
Median dose (IQR) — μg/kg/min 0.29 (0.16–0.52) 0.27 (0.15–0.44)
Epinephrine
No. of patients 21 21
Median dose (IQR) — μg/kg/min 0.14 (0.07–0.28) 0.13 (0.08–0.38)
Vasopressin
No. of patients 33 37
Median dose (IQR) — units/min 0.03 (0.02–0.04) 0.03 (0.02–0.04)
Dobutamine
No. of patients 18 22
Median dose (IQR) — μg/kg/min 5.7 (3.5–8.8) 5.0 (4.4–6.2)
*  There were no significant between‑group differences in the demographic characteristics at baseline. The rates of missing 
values are shown in Table S1 in the Supplementary Appendix. COPD denotes chronic obstructive pulmonary disease, 
and IQR interquartile range.
†  The body‑mass index is the weight in kilograms divided by the square of the height in meters. Data were missing for six 
patients in the levosimendan group and for three in the placebo group.
‡  Race was determined from medical records.
§  Recent surgery was defined as admission to the intensive care unit from the operating room.
¶  The onset of shock was defined as the initiation of vasopressors.
Table 1. Baseline Characteristics.*
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Variable
Levosimendan 
(N = 258)
Placebo 
(N = 257)
Median APACHE II score (IQR)† 25 (21–31) 25 (21–30)
Median SOFA score (IQR)‡ 10 (8–12) 10 (7–12)
Organ failure — no./total no. (%)§
Respiratory 99/257 (38.5) 101/256 (39.5)
Renal 77/258 (29.8) 74/256 (28.9)
Hepatic 6/252 (2.4) 8/252 (3.2)
Coagulation 16/256 (6.2) 13/255 (5.1)
Neurologic 117/224 (52.2) 111/212 (52.4)
Source or site of initial infection — no./total no. (%)
Lung 98/257 (38.1) 103/257 (40.1)
Abdomen 95/257 (37.0) 96/257 (37.4)
Urinary tract 12/257 (4.7) 17/257 (6.6)
Primary bacteremia 7/257 (2.7) 3/257 (1.2)
Neurologic site 4/257 (1.6) 1/257 (0.4)
Soft tissue or catheter 16/257 (6.2) 10/257 (3.9)
Other 25/257 (9.7) 27/257 (10.5)
Positive microbiologic culture — no./total no. (%)¶ 109/258 (42.2) 112/256 (43.8)
Mechanical ventilation — no. (%) 207 (80.2) 210 (81.7)
Renal‑replacement therapy — no. (%) 44 (17.1) 45 (17.5)
Moderate or severe ARDS — no. (%) 72 (27.9) 59 (23.0)
Heart rhythm — no./total no. (%)
Sinus rhythm 201/258 (77.9) 218/255 (85.5)
Atrial fibrillation 32/258 (12.4) 21/255 (8.2)
Paced 3/258 (1.2) 2/255 (0.8)
Other irregular rhythm 22/258 (8.5) 14/255 (5.5)
Median values for physiological variables (IQR)‖
Mean arterial pressure — mm Hg 74 (68–80) 73 (67–79)
Heart rate — beats/min 97 (82–111) 94 (80–110)
Central venous pressure — mm Hg 11 (9–15) 12 (8–16)
Cardiac index — liters/min/m2 2.7 (2.2–3.7) 3.3 (2.2–4.0)
Stroke volume — ml 55.7 (40.0–73.5) 67.0 (49.4–79.7)
Arterial oxygen saturation — % 97 (95–98) 97 (95–98)
Central venous oxygen saturation — % 75 (69–81) 76 (70–81)
Lactate — mmol/liter 2.2 (1.4–3.5) 2.3 (1.5–3.9)
Pao2:Fio2 — mm Hg 216 (151–294) 215 (152–296)
Creatinine — mg/dl 1.6 (1.0–2.4) 1.5 (1.1–2.4)
Bilirubin — mg/dl 0.8 (0.5–1.5) 0.9 (0.5–1.6)
Hemoglobin — g/liter 108 (94–123) 108 (93–125)
Platelet count per mm3 212,000 (134,000–299,000) 216,000 (144,000–308,000)
Glasgow Coma Scale score 9 (3–15) 8 (3–15)
*  There were no significant between‑group differences in the characteristics at baseline, except for stroke volume (P = 0.02). ARDS 
denotes the acute respiratory distress syndrome, Fio2 fraction of inspired oxygen, and Pao2 partial pressure of arterial oxygen.
†  Scores on the Acute Physiology and Chronic Health Evaluation (APACHE) II range from 0 to 72, with higher scores in‑
dicating more severe illness and a higher risk of death.
‡  Scores on the Sequential Organ Failure Assessment (SOFA) were calculated on the basis of six organ systems at base‑
line. Scores range from 0 to 24, with higher scores indicating more severe illness.
§  Renal failure was defined as having an acute kidney injury of stage 3 (urinary‑output criteria omitted because data were 
unavailable)23; other organ failures were defined as a SOFA score of 3 or higher. Cardiovascular failure is not listed here 
because it was an inclusion criterion.
¶  The types of organisms that were identified are shown in Table S2 in the Supplementary Appendix.
‖  The cardiac index and stroke volume were measured in 84 patients in the levosimendan group and in 73 in the placebo group. 
The numbers of missing values for other physiological variables listed here are shown in Table S1 in the Supplementary 
Appendix. To convert the values for creatinine to micromoles per liter, multiply by 88.4. To convert the values for bilirubin to 
micromoles per liter, multiply by 17.1. Scores on the Glasgow Coma Scale range from 3 to 15, with lower scores indicating a 
greater depression of consciousness.
Table 2. Acute Illness and Physiological Variables at Baseline.*
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Outcome
Levosimendan 
(N = 258)
Placebo 
(N = 257)
Absolute Difference 
(95% CI)† P Value
Primary outcome
Mean daily total SOFA score 6.68±3.96 6.06±3.89 0.61 (−0.07 to 1.29) 0.053
Respiratory 1.70±1.18 1.56±1.15 0.14 (−0.06 to 0.34) 0.23
Coagulation 0.75±1.05 0.75±1.02 0.00 (−0.18 to 0.17) 0.55
Hepatic 0.51±0.84 0.45±0.77 0.06 (−0.08 to 0.19) 0.65
Cardiovascular 2.27±1.20 2.02±1.20 0.25 (0.04 to 0.46) 0.01
Renal 1.46±1.49 1.28±1.38 0.18 (−0.07 to 0.42) 0.32
Mean daily SOFA score excluding cardiovascular score 4.41±3.13 4.05±3.07 0.36 (−0.17 to 0.90) 0.12
Mean daily total SOFA score in the sensitivity analysis‡ 7.19±3.72 6.78±3.74 0.41 (−0.24 to 1.06) —
Secondary outcomes
Death — no./total no. (%)§
At 28 days 89/258 (34.5) 79/256 (30.9) 3.6 (−4.5 to 11.7) 0.43
At ICU discharge 83/258 (32.2) 76/257 (29.6) 2.6 (−5.4 to 10.6) 0.59
At hospital discharge 97/258 (37.6) 84/256 (32.8) 4.8 (−3.5 to 13.0) 0.30
Median no. of catecholamine‑free days (IQR) 22 (0 to 26) 23 (0 to 26) −1.0 (−4.5 to 1.0) 0.09
Median no. of ventilation‑free days (IQR) 16 (0 to 25) 19 (0 to 25) −3.0 (−9.5 to 1.0) 0.14
Major acute kidney event over period of 28 days  
— no./total no. (%)
148/258 (57.4) 139/256 (54.3) 3.1 (−5.5 to 11.6) 0.54
Need for new renal‑replacement therapy 62/257 (24.1) 62/257 (24.1) 0.0 (−7.4 to 7.4) >0.99
Sustained renal failure at day 28 or ICU discharge if before 
28 days
118/258 (45.7) 108/257 (42.0) 3.7 (−4.9 to 12.3) 0.45
Median duration of renal‑replacement therapy (IQR) — days 3.0 (1.0 to 8.0) 5.0 (2.0 to 9.0) −2.0 (−3.0 to 0.0) 0.24
Median length of ICU stay (IQR) — days
All patients 7.3 (3.2 to 14.8) 8.3 (3.9 to 13.5) −1.0 (−2.6 to 0.8) 0.66
Survivors 9.1 (5.0 to 16.1) 9.0 (4.9 to 14.1) 0.2 (−2.0 to 2.7) 0.31
Nonsurvivors 3.2 (1.4 to 8.9) 5.7 (2.2 to 11.7) −2.6 (−5.7 to −0.8) 0.09
Median length of hospital stay (IQR) — days
All patients 19.6 (10.1 to 40.4) 22.7 (11.7 to 42.3) −3.1 (−7.0 to 2.2) 0.24
Survivors 30.1 (16.8 to 48) 27.7 (18 to 52.3) 2.5 (−5.9 to 8.2) 0.81
Nonsurvivors 8.2 (3.4 to 18.6) 11.3 (5.1 to 25.7) −3.1 (−6.5 to 0.7) 0.25
Safety outcomes
Any serious adverse event — no. (%)  32 (12.4) 23 (8.9) 3.5 (−2.3 to 9.2) 0.26
Any life‑threatening arrhythmia — no. (%) 15 (5.8)  6 (2.3) 3.5 (−0.3 to 7.3) 0.08
Supraventricular tachyarrhythmia  8 (3.1)  1 (0.4) 2.7 (0.1 to 5.3) 0.04
Bradycardia  0  2 (0.8) −0.8 (−2.2 to 0.7) 0.48
Ventricular fibrillation or tachycardia  7 (2.7)  3 (1.2) 1.5 (−1.2 to 4.3) 0.34
Myocardial infarction or acute coronary syndrome — no. (%)  3 (1.2)  1 (0.4) 0.8 (−1.1 to 2.7) 0.62
Other — no. (%)¶ 18 (7.0) 17 (6.6) 0.4 (−4.3 to 5.1) >0.99
*  Plus–minus values are means ±SD. Absolute differences between percent values are percentage points. Confidence intervals were calculated 
with the use of bootstrap methods for all continuous variables. P values for continuous outcomes were calculated with the use of a Mann–
Whitney test and for binary outcomes with the use of a chi‑square test. ICU denotes intensive care unit.
†  Values may be different than expected owing to rounding.
‡  A prespecified sensitivity analysis that implemented Bayesian models was performed with the use of Markov chain Monte Carlo methods 
(see the Supplementary Appendix). The absolute difference in this analysis is presented with 95% credible intervals, and P values are not 
applicable to this type of analysis.
§  One patient in the placebo group declined follow‑up after discharge from the ICU but before day 28 and hospital discharge.
¶  Other events were defined as any serious adverse event that was not a life‑threatening arrhythmia and not a myocardial infarction or acute 
coronary syndrome.
Table 3. Clinical Outcomes.*
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S13 in the Supplementary Appendix). The num-
ber of catecholamine-free days was 22 days in the 
levosimendan group and 23 in the placebo group 
(difference, −1.0 day; 95% CI, −4.5 to 1.0; P = 0.09). 
A total of 32 patients in the levosimendan group 
had a serious adverse event, as compared with 
23 in the placebo group. Supraventricular tachyar-
rhythmia was significantly more common in the 
levosimendan group than in the placebo group. 
There were no significant differences over time 
between the two groups in the cardiac index, 
stroke volume, central venous oxygen saturations 
or pressure, the ratio of the partial pressure of 
arterial oxygen to the fraction of inspired oxy-
gen, and the serum creatinine and bilirubin 
levels (Figs. S14 through S20 in the Supplemen-
tary Appendix).
There were no significant between-group dif-
ferences in the mean SOFA score or in 28-day 
mortality in the prespecified subgroups. There 
was no significant heterogeneity of treatment 
effect in any of the subgroup analyses (Fig. S21 
in the Supplementary Appendix).
Discussion
In this trial, the addition of levosimendan to 
standard care was not associated with less se-
vere organ dysfunction in adult patients with 
septic shock. Patients who were treated with levo-
simendan required more norepinephrine, had 
higher heart rates, had a higher rate of arrhyth-
mia, and underwent mechanical ventilation for 
longer than those who received placebo.
Levosimendan is an inotropic agent with a 
mechanism of action that differs from that of 
catecholamines. By sensitizing cardiomyocytes 
to existing levels of intracellular calcium, an in-
crease in the force of myocardial contraction is 
achieved with a minimal increase in myocardial 
oxygen demand, in contrast to catecholamines.9 
As calcium levels fall in diastole, relaxation of 
the myocardium is not impaired with levosimen-
dan, which may be an additional benefit over 
catecholamines.26 Although levosimendan has 
a half-life of approximately 1 hour, its active 
metabolite OR-1896 has a half-life of 80 hours. 
Therefore, a single 24-hour infusion should pro-
vide hemodynamic effects over the course of a 
week,27 which is long enough to support the 
majority of patients with septic shock until hemo-
dynamic recovery.20
Preclinical and small clinical trials have shown 
a potential benefit of levosimendan on renal,10 
hepatic,12 and pulmonary28 function in patients 
with sepsis. Therefore, the mean daily SOFA 
score was chosen as the primary outcome in this 
trial to fully assess the clinical efficacy and bio-
logic effect of levosimendan. However, there was 
no evidence of any beneficial effect on the total 
SOFA score or on any individual component of 
the score or on any other clinical outcome. The 
cardiovascular SOFA score was higher in the levo-
simendan group than in the placebo group, 
which reflects the higher doses of norepineph-
rine that were required to maintain the mean 
arterial pressure.
Mortality in our trial population was lower 
than in previous studies of levosimendan in pa-
tients with septic shock. This difference is, at 
least in part, a consequence of the fact that we 
recruited a wide range of patients with sepsis, 
without requiring a low cardiac output as an 
enrollment criterion. Myocardial dysfunction, 
although present in more than 50% of patients 
with septic shock,3 may not always be clinically 
evident, even when cardiac-output monitoring is 
used.29 There were four planned subgroup analy-
ses to examine the effect of levosimendan in 
high-risk patients, including those with a low 
cardiac output, those with impaired oxygen de-
livery to the tissues, and those receiving high-
dose catecholamines. There was no evidence of a 
Figure 2. Kaplan–Meier Estimates of the Probability of Survival to Day 28.
The adjusted hazard ratio for death in the levosimendan group, as com‑
pared with the placebo group, was 1.24 (95% CI, 0.91 to 1.67; P = 0.17).
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beneficial effect of levosimendan in any of these 
prespecified subgroups.
Although levosimendan does not stimulate 
β-adrenoreceptors, a significantly higher heart 
rate was seen in the levosimendan group than in 
the placebo group, most likely owing to vaso-
dilatation but possibly related to the higher rate 
of infusion (i.e., higher dose) of norepinephrine 
in the levosimendan group.30 Similarly, there was 
a higher rate of tachyarrhythmia among patients 
in the levosimendan group than among those in 
the placebo group. These observations may have 
contributed to the lack of overall clinical benefit 
and are consistent with recent data that suggest 
a potential benefit in treating persistent tachy-
cardia in patients with sepsis with the use of 
beta-blockers.31 It is also possible that the higher 
rate of norepinephrine use in the levosimendan 
group than in the placebo group may have con-
tributed to further catecholamine-induced myo-
cardial dysfunction.
This trial has several limitations. We inves-
tigated levosimendan as added to standard care 
rather than a comparison of levosimendan with 
an alternative inotrope, such as dobutamine. 
Less than 10% of the patients in the placebo 
group received dobutamine, although the rate of 
use in the placebo group was higher than in the 
levosimendan group and may explain in part why 
the cardiac index and stroke volume were not 
higher in the levosimendan group than in the 
placebo group. There was no significant differ-
ence in outcome seen in the prespecified sub-
group analysis involving patients with a low car-
diac index; however, the number of patients with 
a measured low cardiac index was small (52 pa-
tients). Similarly, no echocardiographic analyses 
were performed to provide additional detailed 
information about changes in myocardial func-
tion with levosimendan treatment. Therefore, this 
trial cannot provide guidance as to which ino-
trope is best to use in the management of sepsis 
if a low cardiac index is present. The target mean 
arterial pressure of 65 to 70 mm Hg, which was 
recommended in the protocol and reiterated 
at investigator meetings, was frequently exceed-
ed (as in other trials involving patients with 
shock20,32,33), which suggests that the norepi-
nephrine doses that were administered could 
have been reduced in the two trial groups.
In conclusion, in adult patients with septic 
shock, the addition of levosimendan to standard 
care was not associated with less severe organ 
dysfunction or lower mortality. Patients who 
were assigned to receive levosimendan required 
more norepinephrine, were less likely to be suc-
cessfully weaned from mechanical ventilation, 
and had more tachycardia and a higher rate of 
supraventricular arrhythmia than those assigned 
to receive placebo.
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